Silver Book Fact

A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.

Mobley L, Hoerger T, Wittenborn J, Galuska D, et al. Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate. Medical Decision Making. 2006; 26(2): 194-206. http://mdm.sagepub.com/cgi/content/abstract/26/2/194

Reference

Title
Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate
Publication
Medical Decision Making
Publication Date
2006
Authors
Mobley L, Hoerger T, Wittenborn J, Galuska D, et al.
Volume & Issue
Volume 26, Issue 2
Pages
194-206
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Tools to Prevent Secondary Osteoporosis Fractures are Not Being Used
     
  • Reducing secondary bone fractures can reduce medicare spending
    Reducing 5-20 percent of “secondary” bone fractures in 2015 could have reduced Medicare FFS spending by $310 million to $1.2 billion over a follow-up period that lasted up to 2 to…  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by…  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.